Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Migraine
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Migraine
    TopAbstracts in Migraine 09/25/2008 - (DGNews)
    Tezampanel Helps Relieve Migraine Pain: Presented at ANA - (DGDispatch)
    People With Migraine More Likely to Develop Venous Thrombosis - (DGNews)
    TopAbstracts in Migraine 08/28/2008 - (DGNews)
    Frovatriptan Prevents Difficult-to-Treat Menstrual Migraine: Presented at WCP - (DGDispatch)

    News archive

     Recent webcasts/CME - Migraine
      Integrating Menstrual Migraine Management into Women's Healthcare
      Migraine Prevention: What Pharmacists Need to Know

      Webcasts/CME archive

       Recent cases - Migraine
        Acute Bilateral Simultaneous Angle Closure Glaucoma After Topiramate Administration
        A Case of Intermittent Ataxia Associated with Migraine Headaches
        Pneumatized Superior Turbinate as a Cause of Headache
        Transient Monocular Visual Loss and Retinal Migraine
        Hemeplegic Migraine with Leptomeningeal Angiomatosis

        Cases archive
          




        my personal edition > migraine > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Zolmitriptan Nasal Spray Demonstrates Rapid Efficacy for Treatment of Cluster Headache: Presented at IHS

        By Claire Sowerbutt

        KYOTO, JAPAN -- October 17, 2005 -- New data on the intranasal administration of zolmitriptan demonstrate significant efficacy in the treatment of cluster headache, with a rapid onset of action.

        Peter J. Goadsby, MD, PhD, professor of clinical neurology, Institute of Neurology, University College of London, London, United Kingdom, presented the findings here in an oral presentation on October 12th at the 12th Congress of the International Headache Society (IHS).

        Cluster headache is among the most painful type of headache known, and occurs very rapidly. Therefore, all treatments must have a rapid onset of action. The current mainstay therapies are subcutaneous sumatriptan, and oxygen.

        The primary endpoint of the zolmitriptan study was combined rate of response at 30 minutes over 3 migraine attacks. The multicenter, placebo-controlled, double-blind, 2-way crossover study randomized 92 patients to intranasal zolmitriptan 5 mg and 10 mg, or to intranasal placebo. Secondary endpoints included pain-free status at 30 minutes and effects on cranial autonomic symptoms.

        Specifically, 42% of patients on zolmitriptan 5 mg reported headache relief within 30 minutes of administration (P < .003 vs placebo), as did 63% of patients in the 10-mg arm (P < .002 vs placebo). With respect to pain-free status at 30 minutes posttreatment, 28% (P < .003 vs placebo) and 50% (P < .002 vs placebo) responded to both the 5-mg and 10-mg dose, respectively.

        "It's perfectly clear cut in this placebo-controlled trial that zolmitriptan is effective in acute cluster headache," Dr. Goadsby said during his presentation.

        He noted that no serious adverse events were reported in either the placebo or active treatment arms.

        "An advantage of the 5-mg dose in this setting is that there is good safety data for taking 15 mg/day of zolmitriptan. If you are not a person who suffers from cluster headache this might not seem important, but if you are a cluster headache patient it means you can take 3 courses of treatment a day -- if you have 3 attacks a day, that's a big difference to your life," Dr. Goadsby said.

        "Evidence is the core to take our field forward, and I offer this evidence for clinical practice in future," he concluded.


        [Presentation title: Zolmitriptan Nasal Spray is Effective in the Acute Treatment of Cluster Headache: A Double-Blind, Placebo-Controlled Cross-Over Study. Poster C024]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send